thiotepa / Generic mfg. - LARVOL DELTA

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting (ASH 2025) - "During induction, 59% received HDMTX+rituximab (R), 39% received HDMTX+R+additional (A) chemotherapy such as temozolomide (MTR) (15%) and cytarabine/thiotepa (MATRix) (15%)...Thiotepa (TT)/BCNU was used for conditioning in 8 patients, and TT/Busulfan/Cyclophosphamide in 1... HDMTX-based induction chemotherapy is effective in patients with PCNSL, even in those with delayed diagnosis or initiation of therapy. Although a minority of patients received consolidation with ASCT, it was associated with 100% progression-free survival."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Pulmonary Disease • Respiratory Diseases • Transplantation

Single vs double cord blood transplantation: Improved engraftment with comparable efficacy (ASH 2025) - " Between April of 2006 and February of 2025, 315 patients with malignant disease underwent their first single (sCBT) or double CBT (dCBT) using a myeloablative conditioning regimen with FLU 75 mg/m2, TBI 13.2 Gy, CY 120 mg/kg (n=182) or FLU 150 mg/m2, TBI 4 Gy, CY 50 mg/kg, Thiotepa 10 mg/kg (n=47) or Treo 42 g/m2, FLU 150 mg/m2, TBI 2 Gy (n=86)...Graft-versus-host-disease (GVHD) prophylaxis included Cyclosporine and Mycophenolate Mofetil for all patients... In our study, sCBT was not inferior to dCBT with outstanding clinical outcomes. In fact, sCBT was associated with significantly faster neutrophil and platelet recovery. These findings encourage the use of sCBT in patients with an adequate cell dose, offering the potential to substantially reduce the cost of CBT without compromising efficacy."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • CD34 • HLA-B • HLA-DRB1

Haploidentical hematopoietic stem cell transplantation with bussulfan, fludarabine and cyclophosphamide and total body irradiation 200cgy conditioning with post-transplant cyclophosphamide and peripheral blood stem cells as an alternative regimen to reduce graft rejection in sickle cell disease (ASH 2025) - "Graft-versus-host disease (GvHD) prophylaxis included PTCy (50 mg/kg on days +3 and +4), mycophenolate mofetil, and sirolimus. Our data support the feasibility and safety of haploidentical HSCT using busulfan, fludarabine, and cyclophosphamide RIC combined with PTCy and PBSC in adult SCD patients. This approach yielded sustained full donor chimerism with low incidence of severe GvHD and graft failure, offering a practical alternative in resource-limited settings where thiotepa is not easily available. Considering the ongoing challenges in donor availability and conditioning toxicity, further studies with larger cohorts and longer follow-up are warranted to confirm the durability of engraftment, late effects, and overall survival benefits."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Mucositis • Sickle Cell Disease • Transplant Rejection • Transplantation

Efficacy of a second allogeneic hematopoietic cell transplant in myeloid heematologic malignancies (ASH 2025) - "Conditioning regimen: 3 patients encountering graft failure received reduced intensity conditioning, while 9 relapsing patients received total body irradiation (8Gy) and thiotepa (5mg/kg for 2 days) based myeloablative conditioning. GVHD prophylaxis included porcine anti human lymphocyte immunoglobulins, tacrolimus, methotrexate and/or anti-CD25 antibody...Univariate analyses suggested ECOG (>2) and HCT-CI(>1) score were correlated with patient survival after second allo-HCT. Conclusion The findings of our current study indicate that a second allo-HCT is a reasonable treatment choice for AML and MDS patients relapsing or encountering graft failure after a first allo-HCT, complete response and survival benefit may be anticipated particularly in those with better performance status and fewer comorbidities."

Clinical • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Pneumonia • Respiratory Diseases • Transplantation

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy. (ASH 2025) - "Such effect has been retrospectively observed also in the setting of haploidentical alloHCT (Haplo) using post-transplant cyclophosphamide (PTCy), a very-high risk landscape for CMVr and disease...We included adult patients (> 18y.o), with oncohematological diseases, receiving a first Haplo, using myeloablativemor reduced intensity conditioning (RIC) based on thiotepa/fludarabine/busulphan (TBF), peripheral blood stem cells as graft source, a GVHD prophylaxis based on PTCy... LTV is associated to a significant reduction in CMVr also in a high-risk population (Haplo with PTCy) without observing significant differences in terms of NRM. For those patients experiencing CMVr, the previous use of LTV was associated to a delayed reactivation and absence of CMV disease or death. Larger cohort of patients will be necessary to confirm these results"

Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy (ASH 2025) - " 23 pts were referred to holding: 6 partial-brain irradiation, 4 intrathecal CHT, 2 polatuzumab vedotin, 5 ibrutinib, 1 HD-ifosfamide-based CHT, 2 MATRix regimen, 1 thiotepa-based ASCT, combinations of these strategies in 2...Only one pt experienced G3-4 CRS, all CRS cases were successfully treated with tocilizumab and steroids, anakinra was used in 2 cases... Varied presentation and high aggressivity of SCNSL impede the use of a uniform treatment for these pts. SCNSL refractory to HDMTX-based polyCHT can benefit significantly from a tailored multimodal holding based on the pt's history and extension of disease. Only pts with good PS and responsive to holding therapy should be offered CAR-T to avoid superfluous toxicity."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Efficacy and safety of bmetl regimen (Orelabrutinib plus Semustine, Temozolomide and Lenalidomide) with subsequent maintenance treatment in elderly/frail patients with CNSL (ASH 2025) - "After induction therapy, patients with objective response received sequential MT regimen (methotrexate 3 mg/m 2 , day 1; thiotepa 20 mg/m 2 , day 2) in a 21-day cycle for 2-4 cycles... BMeTL regimen with subsequent maintenance treatment is effective and well-tolerated for elderly/frail patients with CNSL. This study provides a potential novel strategy for this elderly/frail population."

Clinical • Agranulocytosis • CNS Lymphoma • Geriatric Disorders • Granulocytopenia • Hematological Malignancies • Infectious Disease • Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China (ASH 2025) - "Polatuzumab vedotin, an anti-CD79b monoclonal antibody, when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), offers the benefits of more convenient administration and comparable safety to the R- CHOP regimen, while demonstrating reduced toxicity comparison to DA-EPOCH-R...Another patient attained CMR following R-ESHAP treatment for lymph node relapse, whereas one succumbed to CNS relapse despite receiving multiple therapies, including surgery, HD-MTX BV, selinexor, and thiotepa.5 patients received targeted therapies...Summary/Conclusion POLA-R-CHP shows potential as an efficient therapy for PMBCL. Its frontline application could enhance overall response rates while reducing treatment-related toxicity."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Renal Disease • Respiratory Diseases • CD79B

Transplant outcomes of b acute lymphoblastic leukemia treated with inotuzumab ozogamicin with mini–Hyper-CVD based chemo-immunotherapy (ASH 2025) - "The chemotherapy protocol consisted of mini-CVD part A(cyclophosphamide at 150mg/m2 x 4 doses, dexamethasone 20mg x 4 days, vincristine 1.5mg on day 1and 8, but no anthracycline) or part B (methotrexate 250mg/m2 and cytarabine 0.5gm/m2 x 4 doses)...CD22 expression was positive in 22patients (91.4%), Other therapies added to this regimen included tyrosine kinase inhibitors in 3 patients(12.5%), venetoclax in 13 patients (54%), and rituximab in 11 patients (45.3%).The overall response rate (ORR) was 95.8% (n = 23)...Conditioning regimens included Flu/TBI in 12 patients, Fludarabine(Flu)/Melphalan (Mel) in 2 patients, Flu/Mel/Total Body Irradiation (TBI) in 4 patients,Flu/Cyclophosphamide/TBI in 2 and Flu/Thiotepa/TBI in 1. Graft versus host disease prophylaxis varied,with post-transplant cyclophosphamide (PTCy) /Cyclosporine (CsA)/mycophenolate mofetil (MMF) used in15 patients, PTCy/CSA in 5, and CSA/methotrexate in 1...InO mini CVD is a feasible and effective salvage..."

IO biomarker • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Neutropenia • Septic Shock • Transplantation • CD20 • CD22 • CD34 • TP53

Study on five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation Patients—Achieving zero infection through data-driven and optimized nursing schemes (ASH 2025) - "Transplant types:599 cases of haploidentical transplantation (74%), 155 cases of fully matched transplantation (19.2%), 187cases of unrelated transplantation (23.1%), and 224 cases of secondary transplantation (27.7%).Conditioning regimens: including 399 cases with total body irradiation (TBI), 320 cases with busulfan (BU),272 cases with etoposide, 54 cases with cyclophosphamide (CTX), as well as other drugs such asfludarabine, ATG, cytarabine, thiotepa, etc. (patients often receive combinations containing multipledrugs). The data-driven closed-loop management model combined with continuously improved andoptimized nursing measures can effectively reduce the incidence of perianal infection. Through thecircular mechanism of "data feedback - measure iteration - innovative application", precise protectionfrom the conditioning period to the immune recovery period is realized. This model has successfullypromoted the fundamental transformation of nursing practice..."

Clinical • Bone Marrow Transplantation • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Lymphoma • Mucositis • Multiple Myeloma • Transplantation

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant. (ASH 2025) - "Treosulfan-based group: thiotepa-treosulfan-fludarabine (TTF) or thiotepa-etoposide-cyclophosphamide fludarabine-treosulfan (TEC-FT) regimens.Busulfan-based group: thiotepa-busulfan-fludarabine (TBF) or thiotepa-etoposide-cyclophosphamidebusulfan-fludarabine (TEC-BF) regimens. There were similar 1-year OS, CIR, GRFS rates and adverse events.Limitations of this retrospective analysis include small sample size predisposing to potential samplingbias. Randomized prospective studies are needed to assess the potential of double alkylator combinationof thiotepa and treosulfan in adults with haematological malignancies."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Liver Failure • Mucositis • Oncology • Portal Hypertension • Transplantation

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party (ASH 2025) - "These findings indicatethat lower thiotepa doses (<8 mg/kg) may be preferable, regardless of conditioning intensity.Additionnaly, among TBF-MAC treated patients, those transplanted in CR2 had higher risk of relapse andmortality. Irrespective of TBF regimen, the use of peripheral blood stem cell grafts increased aGVHD riskwithout affecting OS or RI, and older age and lower Karnofsky performance scores remain adverseprognostic factors for survival."

Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity (ASH 2025) - "The conditioning regimen included: Busulfan 3.2 g/kg/day ondays -8 and -7; thiotepa 10 mg/kg/day on day -6; cyclophosphamide 20 mg/kg/day on day -5 to -2; rabbitanti-thymocyte globulin (rATG) 2.5 mg/kg/day on day -5 to -2. Five patients had mild pericardial effusion, with amedian onset of 3 days prior to infusion; none required medical intervention. Among the 20 patients, twodeveloped grade III-IV aGVHD, one developed bronchiolitis obliterans syndrome (BOS), one developedEpstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder (PTLD), and oneexperienced cytomegalovirus (CMV) infection.ConclusionOur study demonstrates that a thiotepa-containing conditioning regimen with reducedcyclophosphamide is safe and effective in pediatric AA at risk of cadiotoxicity."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cardiovascular • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Transplantation

Thiotepa and busulfan combined with cyclophosphamide conditioning regimen plus maintenance therapy improved the disease-free survival of patients with relapsed/refractory haematologic malignancies after undergoing allogeneic transplantation (ASH 2025) - "Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation. This study suggests that the TBC conditioning regimen may be a promising option forpatients with R/R haematologic diseases undergoing allo-HSCT."

Clinical • Bone Marrow Transplantation • Central Nervous System Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • Transplantation

Efficacy and safety of rituximab, high-dose methotrexate, and thiotepa (R-MT) as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma (ASH 2025) - "The IELSG 32 study confirmed that a thiotepa-containing multi-drugcombination regimen (rituximab + high-dose methotrexate + cytarabine + thiotepa, MATrix) achieves anoverall objective response rate (ORR) of 87% when used as induction therapy for PCNSL...At a median follow-up of 19 months, the 2-year PFS rateand OS rate were 63.9% and 82.9%, respectively.Based on subsequent treatment strategies, patients were divided into three groups: 15 patients receivedinduction therapy alone, 16 patients received sequential maintenance therapy (including Bruton tyrosinekinase inhibitors [BTKi: 7 with zanubrutinib, 4 with orelabrutinib] or immunomodulatory drugs [IMiD: 5with lenalidomide, 1 with pomalidomide]), and 5 patients received ASCT as consolidation therapy.Subgroup analysis showed that the proportion of patients aged > 60 years in the sequential maintenancetherapy group was 81.3%, which was significantly higher than that in the other two groups (81.3% vs.53.3% vs. 0%,..."

Clinical • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Respiratory Diseases

Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project. (ASH 2025) - "Intensive HD-MTX regimens were defined as including high dose cytarabine with or without thiotepa. HD-MTX alone orwith less intensive agents such as procarbazine were considered non-intensive...Patients receiving urgent chemotherapy had worse OS. Patients who undergoASCT experience have very good outcomes, although its application as first-line consolidation for PCNSLvaries markedly between regions, potentially contributing to geographical variation in survival."

CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation (ASH 2025) - "This study compared clinical outcomes ofconsolidation ASCT according to conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC),busulfan/thiotepa (BuTT), and non-thiotepa regimens. This retrospective study included 160 newly diagnosed PCNSL patients treated at Asan MedicalCenter from 2004 to 2023 who responded to HD-MTX-based induction chemotherapy and proceeded toconsolidation ASCT. Induction regimens included HD-MTX, HD-MTX/procarbazine/vincristine (MPV), orrituximab-MPV (R-MPV). Patients were categorized by conditioning regimen: non-thiotepa(busulfan/cytarabine/etoposide[BuCyE], busulfan/melphalan/etoposide[BuMelE], orBCNU/etoposide/cytarabine/melphalan[BEAM]; n=28), TBC (n=71), and BuTT (n=61)... This study demonstrated that thiotepa-based conditioning regimens were associated withsuperior survival outcomes compared to non-thiotepa regimens for consolidation HDC-ASCT in PCNSLpatients. Among thiotepa-based regimens, BuTT and TBC showed comparable survival..."

Clinical • Clinical data • CNS Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Central Nervous System Lymphoma • Respiratory Diseases • Septic Shock • Transplantation

Efficacy and safety of the TEAM conditioning for autologous stem cell transplantation in lymphoma patients with high-risk of central nervous system relapse (ASH 2025) - "In this study, we evaluated the efficacy and safety of the TEAM regimen (thiotepa,etoposide, cytarabine, and melphalan) in ASCT for NHL patients at high risk for CNS involvement. We retrospectively analyzed the clinical data of NHL patients at high-risk of CNS relapse whounderwent ASCT with TEAM conditioning between January 1, 2021, and May 31, 2025... ASCT with TEAM conditioning appears to be effective and well-tolerated in NHL patients athigh-risk of CNS relapse. The potential clinical benefit of ASCT in this difficult-to-treat population warrantsfurther validation in prospective studies."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Mucositis • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Respiratory Diseases • Secondary Central Nervous System Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study) (ASH 2025) - "In the intensive treatment cohort, 229 pts (69.4%) received rituximab (R) containing therapy. Most pts(272 pts, 82.4%) received HD-MTX based regimens as salvage therapy at first cycle, including HD-MTX ± R(52.2%) and MPV (HD-MTX, procarbazine and vincristine) ± R (46.7%). The remaining 58 pts (17.6%)received non-HD-MTX-based regimens, including HD-cytarabine-based (60.4%), CHOP-like (8.6%) andplatinum-based regimens (12.1%)...Pts who received busulfanand thiotepa (BuTT) conditioning (n = 23) showed better outcomes than those who received non-BuTTconditioning (n = 28) (3-year OS: 87.5% vs. 66.0%, p = 0.033). Although HD-MTX-based regimens were most frequent, this study revealed heterogeneity in first-linesalvage therapies for rSCNSL, highlighting the need for optimal tretament strategies. Addition of R andconsolidative HDT/ASCT (particularly BuTT) might be associated with improved OS and PFS."

Retrospective data • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes (ASH 2025) - "Myeloablative conditioning (MAC) wasdefined as busulfan AUC ≥20,000 μmol/min or ≥16,000 μmol/min with thiotepa...Post-transplant cyclophosphamide (PTCy) wasadministered in 179 (42%).At the time of SCT, 65/427 (15%) had transformed to acute myeloid leukemia (AML) and were excludedfrom further analysis... SCT is a curative strategy in 69% of patients with TP53 wild-type MDS. Use of venetoclax as apre-SCT cytoreductive regimen should be explored in larger studies. Outcomes remain poor in TP53-mutated disease and alternative approaches are needed in this population."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Transplantation • TP53

A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRαβ cell depleted HCT (ASH 2025) - "The diseasestatus at TDH were 40 at CR1, 42 at CR2, 19 at > CR3 or progress ( the latter two (≥ CR2) together was 61 ).Patients received different conditioning regimens composed of Busulfan or Melphalan,Cyclophosphamide, Fludalabine and Thiotepa, and the doses of them were adjusted according to thedisease status and kinds...All patients received Decitabine plus DLI,monthly for 6 time...None of relapse occurred in the CR1 group. Inthe ≥ CR2 group the UCB subgroup showed a PTR reduced tendency."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • CD34

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up. (ASH 2025) - "The conditioning regimen was fludarabine and reduced dose intravenous busulfan (FluBu, total6.4-8 mg/kg, n=25), the combination of fludarabine thiotepa, busulfan (TBF, n=61) or other regimens(n=16). Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and methotrexate ormycophenolate. All patients also recieved Anti thymocyte globulin (ATG, Grafalon) during conditioning.With a median follow-up of 5.6 years (range, 0.1-22 years), 56 are alive and 46 have died, 30 of non-relapse causes and 16 of relapse...Azacytidine and venetoclax was the most frequenttreatment for patients relapsing as AML...Allogeneic HSCT can allow long-term survival and possible cure for patients with myelofibrosis. However,long-term survivors are at continuous risk for late relapse and late NRM. For those who are not cured,HSCT may reset the pattern of progression of the myeloproliferative process."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelofibrosis • Polycythemia Vera • Transplantation

Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion (ASH 2025) - "Sex, a second Allo-HSCT, donor type, graft source,TBI, busulfan, melphalan, thiotepa, and any grade of cGVHD or moderate-severe cGVHD were notsignificantly associated with SPMs...Fludarabine (HR 1.9; 95% CI,0.9–4.4; p=0.1) and treosulfan (HR 1.8; 95% CI, 0.8–4.4; p=0.2) lost statistically significance. SPMs remain a significant late complication after Allo-HSCT... SPMs remain a significant late complication after Allo-HSCT. GVHD prophylaxis with ATG orPTCy was not associated with increased SPM risk. Age at transplant >50y was the only independent riskfactor identified."

Preclinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lung Cancer • Lymphoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • Transplantation

Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study (ASH 2025) - P2 | "Twenty-three (76.7%) patients receivedepcoritamab in combination with lenalidomide (n=14, 46.7%), ibrutinib (n=5, 16.7%), pomalidomide (n=5,16.7%), rituximab (n=4, 13.2%) or with polychemotherapies (n=3, 10.7%)...Ten (90.9%) patients received glofitamab in combination with ibrutinib (n=7,63.6%), lenalidomide (n=6, 54.5%) or pomalidomide (n=2, 18.1%)...Nineresponder patients received a subsequent treatment, with axicabtagene ciloleucel CAR-T cell therapy (n =7 including 3 CR and 4 PR), thiotepa based IC + ASCT (n = 1 PR) and allogenic stem cell transplant (n = 1CR)... CD3xCD20 BsAbs resulted in encouraging response rates with expected toxicities in heavilypretreated R/R P/SCNSL patients including patients treated with prior CAR-T cell therapy. BsAbs is anoption to be considered for R/R SCNSL and these encouraging results highlight the need for prospectivetrials testing their role in this setting. A prospective trial testing epcoritamab in R/R PCNSL began inFrance..."

Retrospective data • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis (ASH 2025) - "First-line treatments were mainly HD-MTX alone (38%),HD-MTX + temozolomide (17%), or vincristine + procarbazine (12%)...Twelve patients (29%) underwent consolidative autologoustransplant, most commonly with thiotepa/carmustine (TT/BCNU, 69%) or BEAM conditioning (25%).Median duration of follow-up was 10.4 months... Forty-two pts met inclusion criteria. Median age was 57 (range 19–77), 69% were male, and 79%were white. Most (69%) had ECOG 0–1."

Retrospective data • CNS Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Organ Transplantation • T Cell Non-Hodgkin Lymphoma • ALK • DNMT3A • TP53